Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Zenos Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$5,451,694

542 payments

Through program year 2025, Zenos Clinical Research is reported as receiving $5,451,694 in research payments, across 542 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $5,195,918 523
2024 Research $248,481 10
2023 Research $5,544 3
2022 Research $1,750 6

Breakdown

Who paid Research payments · program years 2022–2025
  1. Vertex Pharmaceuticals Incorporated $4,238,083 7 payments
  2. Boehringer Ingelheim International GmbH $650,862 460 payments
  3. Novartis Pharmaceuticals Corporation $404,540 2 payments
  4. Amgen Inc. $52,821 3 payments
  5. Pfizer Inc. $35,428 6 payments
  6. Ipsen Innovation $34,697 50 payments
  7. Invivyd Inc $18,105 2 payments
  8. Moderna TX, Inc. $10,475 9 payments
  9. Biogen, Inc. $4,974 1 payment
  10. Braintree Laboratories, Inc. $1,710 2 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy $3,748,872 3 payments
  2. A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis $623,361 432 payments
  3. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $404,540 2 payments
  4. A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy $387,977 1 payment
  5. A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease $99,767 2 payments
  6. An Interventional Efficacy and Safety Phase 3 Randomized Doubleblind 3Arm Study to Investigate Ibuzatrelvir in Adults With Symptomatic Covid19 Who Are Severely Immunocompromised $24,124 4 payments
  7. BI 456906 in NASH F4 - pivotal trial $22,466 15 payments
  8. A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) $22,329 1 payment
  9. Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants $18,998 24 payments
  10. Canopy $18,105 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record